Tags

Type your tag names separated by a space and hit enter

Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Neurology. 2003 Apr 08; 60(7):1125-9.Neur

Abstract

BACKGROUND

The antiparkinsonian drug L-dopa causes increased cellular synthesis of homocysteine and consequent hyperhomocysteinemia in rats. This effect of L-dopa on plasma homocysteine is accentuated under conditions of impaired homocysteine metabolism such as folate deficiency.

OBJECTIVE

To investigate the effect of L-dopa administration and B-vitamin status on plasma homocysteine concentrations in humans with PD.

METHODS

Plasma homocysteine, folate, vitamin B(12), and pyridoxal-5'-phosphate (PLP) concentrations were determined in 40 individuals diagnosed with idiopathic PD who were being treated as outpatients at the Boston University Medical Center Neurology Clinic. Twenty of the patients were on L-dopa therapy (treatment group) and 20 were L-dopa-naive (control group).

RESULTS

The mean plasma homocysteine concentration was higher in the treatment group than in the controls (p = 0.018). Plasma homocysteine was correlated with plasma folate, vitamin B(12), and PLP concentrations in the treatment group (p <or= 0.007) but not in the controls.

CONCLUSION

L-Dopa can cause hyperhomocysteinemia in PD patients, the extent of which is influenced by B-vitamin status. The B-vitamin requirements necessary to maintain normal plasma homocysteine concentrations are higher in L-dopa-treated patients than in those not on L-dopa therapy. B-Vitamin supplements may be warranted for PD patients on L-dopa therapy.

Authors+Show Affiliations

Vitamin Bioavailability Lab, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA. jwmiller@ucdavis.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12682318

Citation

Miller, J W., et al. "Effect of L-dopa On Plasma Homocysteine in PD Patients: Relationship to B-vitamin Status." Neurology, vol. 60, no. 7, 2003, pp. 1125-9.
Miller JW, Selhub J, Nadeau MR, et al. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology. 2003;60(7):1125-9.
Miller, J. W., Selhub, J., Nadeau, M. R., Thomas, C. A., Feldman, R. G., & Wolf, P. A. (2003). Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology, 60(7), 1125-9.
Miller JW, et al. Effect of L-dopa On Plasma Homocysteine in PD Patients: Relationship to B-vitamin Status. Neurology. 2003 Apr 8;60(7):1125-9. PubMed PMID: 12682318.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. AU - Miller,J W, AU - Selhub,J, AU - Nadeau,M R, AU - Thomas,C A, AU - Feldman,R G, AU - Wolf,P A, PY - 2003/4/12/pubmed PY - 2003/4/24/medline PY - 2003/4/12/entrez SP - 1125 EP - 9 JF - Neurology JO - Neurology VL - 60 IS - 7 N2 - BACKGROUND: The antiparkinsonian drug L-dopa causes increased cellular synthesis of homocysteine and consequent hyperhomocysteinemia in rats. This effect of L-dopa on plasma homocysteine is accentuated under conditions of impaired homocysteine metabolism such as folate deficiency. OBJECTIVE: To investigate the effect of L-dopa administration and B-vitamin status on plasma homocysteine concentrations in humans with PD. METHODS: Plasma homocysteine, folate, vitamin B(12), and pyridoxal-5'-phosphate (PLP) concentrations were determined in 40 individuals diagnosed with idiopathic PD who were being treated as outpatients at the Boston University Medical Center Neurology Clinic. Twenty of the patients were on L-dopa therapy (treatment group) and 20 were L-dopa-naive (control group). RESULTS: The mean plasma homocysteine concentration was higher in the treatment group than in the controls (p = 0.018). Plasma homocysteine was correlated with plasma folate, vitamin B(12), and PLP concentrations in the treatment group (p <or= 0.007) but not in the controls. CONCLUSION: L-Dopa can cause hyperhomocysteinemia in PD patients, the extent of which is influenced by B-vitamin status. The B-vitamin requirements necessary to maintain normal plasma homocysteine concentrations are higher in L-dopa-treated patients than in those not on L-dopa therapy. B-Vitamin supplements may be warranted for PD patients on L-dopa therapy. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/12682318/Effect_of_L_dopa_on_plasma_homocysteine_in_PD_patients:_relationship_to_B_vitamin_status_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&amp;pmid=12682318 DB - PRIME DP - Unbound Medicine ER -